File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections

TitleSerum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections
Authors
Keywordsanti-neuraminidase antibody
cross-reactive antibody
Influenza
pandemic H1N1
protection
seasonal H1N1
sero-diagnosis
Issue Date2019
PublisherTaylor & FrancisGroup, on behalf of Shanghai ShangyixunCultural Communication Co., Ltd. The Journal's web site is located at https://www.tandfonline.com/toc/temi20/current
Citation
Emerging Microbes & Infections, 2019, v. 8 n. 1, p. 404-12 How to Cite?
AbstractHaemagglutination inhibition (HAI) antibody titres are a correlate of protection for influenza virus infection, but several studies have also demonstrated the protective role of anti-neuraminidase (anti-NA) antibodies. However, there is limited data on anti-NA antibody responses in naturally occurring human influenza. We investigated anti-NA antibody responses to pandemic N1 and seasonal N1 in 18 RT-PCR-confirmed patients with naturally acquired pandemic influenza A (H1N1) 2009 disease detected as part of a prospective community study of influenza. There were increases in neuraminidase inhibition (NAI) antibody titres to both pandemic and seasonal N1 antigens, with greater fold increases in those who had low levels of anti-pandemic N1 titres in acute sera. Of 18 patients with pandemic H1N1 infection, fourfold increases in antibody were observed by HAI in 11 (61%) patients, by anti-pandemic N1 inhibition in 13 (72%) or either in 15 of them (83%). Prior seasonal H1N1 virus infections had elicited cross-reactive anti-pandemic N1 antibody titres in some people prior to the emergence of the 2009 pandemic H1N1 virus. Antibody responses to the anti-N1 pandemic 2009 virus and cross-reactive responses to anti-seasonal N1 antibody were seen in influenza A pandemic 2009 infections. NAI antibodies can complement HAI antibody in sero-diagnosis and sero-epidemiology.
Persistent Identifierhttp://hdl.handle.net/10722/269562
ISSN
2023 Impact Factor: 8.4
2023 SCImago Journal Rankings: 2.316
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKarunarathna, HMTK-
dc.contributor.authorPerera, RAPM-
dc.contributor.authorFang, J-
dc.contributor.authorYen, H-
dc.contributor.authorCowling, BJ-
dc.contributor.authorPeiris, JSM-
dc.date.accessioned2019-04-24T08:10:13Z-
dc.date.available2019-04-24T08:10:13Z-
dc.date.issued2019-
dc.identifier.citationEmerging Microbes & Infections, 2019, v. 8 n. 1, p. 404-12-
dc.identifier.issn2222-1751-
dc.identifier.urihttp://hdl.handle.net/10722/269562-
dc.description.abstractHaemagglutination inhibition (HAI) antibody titres are a correlate of protection for influenza virus infection, but several studies have also demonstrated the protective role of anti-neuraminidase (anti-NA) antibodies. However, there is limited data on anti-NA antibody responses in naturally occurring human influenza. We investigated anti-NA antibody responses to pandemic N1 and seasonal N1 in 18 RT-PCR-confirmed patients with naturally acquired pandemic influenza A (H1N1) 2009 disease detected as part of a prospective community study of influenza. There were increases in neuraminidase inhibition (NAI) antibody titres to both pandemic and seasonal N1 antigens, with greater fold increases in those who had low levels of anti-pandemic N1 titres in acute sera. Of 18 patients with pandemic H1N1 infection, fourfold increases in antibody were observed by HAI in 11 (61%) patients, by anti-pandemic N1 inhibition in 13 (72%) or either in 15 of them (83%). Prior seasonal H1N1 virus infections had elicited cross-reactive anti-pandemic N1 antibody titres in some people prior to the emergence of the 2009 pandemic H1N1 virus. Antibody responses to the anti-N1 pandemic 2009 virus and cross-reactive responses to anti-seasonal N1 antibody were seen in influenza A pandemic 2009 infections. NAI antibodies can complement HAI antibody in sero-diagnosis and sero-epidemiology.-
dc.languageeng-
dc.publisherTaylor & FrancisGroup, on behalf of Shanghai ShangyixunCultural Communication Co., Ltd. The Journal's web site is located at https://www.tandfonline.com/toc/temi20/current-
dc.relation.ispartofEmerging Microbes & Infections-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectanti-neuraminidase antibody-
dc.subjectcross-reactive antibody-
dc.subjectInfluenza-
dc.subjectpandemic H1N1-
dc.subjectprotection-
dc.subjectseasonal H1N1-
dc.subjectsero-diagnosis-
dc.titleSerum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections-
dc.typeArticle-
dc.identifier.emailPerera, RAPM: mahenp@hku.hk-
dc.identifier.emailFang, J: vickyf@hku.hk-
dc.identifier.emailYen, H: hyen@hku.hk-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.authorityPerera, RAPM=rp02500-
dc.identifier.authorityYen, H=rp00304-
dc.identifier.authorityCowling, BJ=rp01326-
dc.identifier.authorityPeiris, JSM=rp00410-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1080/22221751.2019.1572433-
dc.identifier.scopuseid_2-s2.0-85063690041-
dc.identifier.hkuros297400-
dc.identifier.volume8-
dc.identifier.issue1-
dc.identifier.spage404-
dc.identifier.epage12-
dc.identifier.isiWOS:000462213900001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl2222-1751-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats